221 related articles for article (PubMed ID: 27714851)
1. Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody.
Oyama S; Kitamura H; Kuramochi T; Higuchi Y; Matsushita H; Suzuki T; Goto M; Adachi H; Kasutani K; Sakamoto A; Iwayanagi Y; Kaneko A; Nanami M; Fujii E; Esaki K; Takashima Y; Shimaoka S; Hattori K; Kawabe Y
Exp Dermatol; 2018 Jan; 27(1):14-21. PubMed ID: 27714851
[TBL] [Abstract][Full Text] [Related]
2. Repeated administration of IL-31 upregulates IL-31 receptor A (IL-31RA) in dorsal root ganglia and causes severe itch-associated scratching behaviour in mice.
Arai I; Tsuji M; Miyagawa K; Takeda H; Akiyama N; Saito S
Exp Dermatol; 2015 Jan; 24(1):75-8. PubMed ID: 25381841
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis.
Nakashima C; Otsuka A; Kabashima K
Exp Dermatol; 2018 Apr; 27(4):327-331. PubMed ID: 29524262
[TBL] [Abstract][Full Text] [Related]
4. Interleukin (IL) 31 induces in cynomolgus monkeys a rapid and intense itch response that can be inhibited by an IL-31 neutralizing antibody.
Lewis KE; Holdren MS; Maurer MF; Underwood S; Meengs B; Julien SH; Byrnes-Blake KA; Freeman JA; Bukowski TR; Wolf AC; Hamacher NB; Rixon MW; Dillon SR
J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):142-150. PubMed ID: 27501029
[TBL] [Abstract][Full Text] [Related]
5. A single dose of interleukin-31 (IL-31) causes continuous itch-associated scratching behaviour in mice.
Arai I; Tsuji M; Takeda H; Akiyama N; Saito S
Exp Dermatol; 2013 Oct; 22(10):669-71. PubMed ID: 24079740
[TBL] [Abstract][Full Text] [Related]
6. IL-4 and IL-13 are not involved in IL-31-induced itch-associated scratching behaviour in mice.
Kawai R; Ichimasu N; Katagiri K
Exp Dermatol; 2024 Jun; 33(6):e15115. PubMed ID: 38855893
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-31 Receptor A Expression in the Dorsal Root Ganglion of Mice with Atopic Dermatitis.
Arai I; Saito S
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674561
[TBL] [Abstract][Full Text] [Related]
8. Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis.
Kato A; Fujii E; Watanabe T; Takashima Y; Matsushita H; Furuhashi T; Morita A
J Dermatol Sci; 2014 Jun; 74(3):229-35. PubMed ID: 24667097
[TBL] [Abstract][Full Text] [Related]
9. IL-4 Augments IL-31/IL-31 Receptor Alpha Interaction Leading to Enhanced Ccl 17 and Ccl 22 Production in Dendritic Cells: Implications for Atopic Dermatitis.
Miake S; Tsuji G; Takemura M; Hashimoto-Hachiya A; Vu YH; Furue M; Nakahara T
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31434203
[TBL] [Abstract][Full Text] [Related]
10. Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis.
Grimstad O; Sawanobori Y; Vestergaard C; Bilsborough J; Olsen UB; Grønhøj-Larsen C; Matsushima K
Exp Dermatol; 2009 Jan; 18(1):35-43. PubMed ID: 19054054
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological profiles and clinical findings of nemolizumab as treatment for pruritus associated with atopic dermatitis].
Kaneda N
Nihon Yakurigaku Zasshi; 2023; 158(3):282-289. PubMed ID: 37121713
[TBL] [Abstract][Full Text] [Related]
12. Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis.
Furue M; Yamamura K; Kido-Nakahara M; Nakahara T; Fukui Y
Allergy; 2018 Jan; 73(1):29-36. PubMed ID: 28670717
[TBL] [Abstract][Full Text] [Related]
13. Nemolizumab: First Approval.
Keam SJ
Drugs; 2022 Jul; 82(10):1143-1150. PubMed ID: 35834124
[TBL] [Abstract][Full Text] [Related]
14. Anti-IL-31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice.
Kasutani K; Fujii E; Ohyama S; Adachi H; Hasegawa M; Kitamura H; Yamashita N
Br J Pharmacol; 2014 Nov; 171(22):5049-58. PubMed ID: 24946165
[TBL] [Abstract][Full Text] [Related]
15. Involvement of interleukin-31 receptor A in morphine-induced itching and antinociception in mice.
Tsuji M; Arai I; Miyagawa K; Miyagishi H; Saito A; Takeda K; Takeda H; Akiyama N; Saito S
Eur J Pain; 2019 Feb; 23(2):378-388. PubMed ID: 30176108
[TBL] [Abstract][Full Text] [Related]
16. Nemolizumab for atopic dermatitis.
Labib A; Vander Does A; Yosipovitch G
Drugs Today (Barc); 2022 Apr; 58(4):159-173. PubMed ID: 35412530
[TBL] [Abstract][Full Text] [Related]
17. Capsaicin suppresses interleukin-31-induced itching partially involved in inhibiting the expression of dorsal root ganglion interleukin-31 receptor A in male mice.
Arai I; Tsuji M; Takeda H; Akiyama N; Saito S
Neurobiol Pain; 2022; 11():100088. PubMed ID: 35400013
[TBL] [Abstract][Full Text] [Related]
18. Itch in dermatomyositis: the role of increased skin interleukin-31.
Kim HJ; Zeidi M; Bonciani D; Pena SM; Tiao J; Sahu S; Werth VP
Br J Dermatol; 2018 Sep; 179(3):669-678. PubMed ID: 29494763
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-4 and interleukin-13 evoke scratching behaviour in mice.
Campion M; Smith L; Gatault S; Métais C; Buddenkotte J; Steinhoff M
Exp Dermatol; 2019 Dec; 28(12):1501-1504. PubMed ID: 31505056
[TBL] [Abstract][Full Text] [Related]
20. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study.
Nemoto O; Furue M; Nakagawa H; Shiramoto M; Hanada R; Matsuki S; Imayama S; Kato M; Hasebe I; Taira K; Yamamoto M; Mihara R; Kabashima K; Ruzicka T; Hanifin J; Kumagai Y
Br J Dermatol; 2016 Feb; 174(2):296-304. PubMed ID: 26409172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
